The three isoforms of transforming growth factor-,8 have previously been implicated in embryonic development of the heart as well as in repair of myocardial damage after ischemia/reperfusion injury. TGF-ft1 has also been localized intracellularly to both mitochondria and contractile filaments of cardiac myocytes, although its role in these structures has not been defined. We now report that exogenous TGF-,6 stabilizes the beating rate of neonatal rat cardiac myocytes cultured on fibroblast matrix, and sustains their spontaneous rhythmic beating in serum-free medium. Moreover, using blocking antibodies to TGF-j3, we show that endogenous TGF-ft secreted by these myocytes acts in an autocrine fashion to maintain their beating rate. In contrast, IL-1,6, an inflammatory mediator secreted by immune cells during myocardial injury, inhibits the beating of cardiac myocytes, and TGF-ft can overcome this inhibition. The antagonistic effects of TGF-,# and IL-1 were not observed when the myocytes were cultured on gelatin, as compared to native fibroblast matrix. The data indicate that TGF-,8 is an important regulator of contractile function of the heart and have significant implications for understanding cardiac physiology in health and disease. (J. Clin. Invest. 1992.90:2056-2062.
Introduction
Little is known regarding the roles of peptide growth factors (cytokines) in regulating cardiac function, although it is known that the myocardium produces several growth factors and that their expression is highly regulated during both embryonic development and disease in the adult (1) . One of these cytokines, transforming growth factor-e (TGF-f3),' is expressed at high levels in the heart during both embryonic and adult life (2, 3) . In embryonic development ofthe heart, TGF-, has been implicated both in morphogenesis of the cushion tissue which will form the heart valves and in the epithelial-tomesenchymal transformation of valve progenitor cells (4-7).
The three isoforms of TGF-fl, TGF-,3's 1, 2, and 3, whose bio-logical activities in vitro are most often indistinguishable (8) , are differentially expressed during early development of the heart. However, at later stages of embryogenesis and in the adult, all three isoforms ofTGF-(B are expressed in the myocardium (K. Flanders, personal communication).
TGF-# plays a central role in the repair ofmany tissues after injury (8) . Recently, attention has turned to its effects in repair or modulation ofcardiac tissue damage resulting from myocardial ischemia or infarction. Studies on the immunohistochemical staining patterns of TGF-( 1 in the heart after experimental myocardial infarction have demonstrated that staining for TGF-# I is quickly lost in ischemic areas (2) . However, certain cells around the margins ofthe infarct begin staining intensely for TGF-( l 24-48 h after infarction, leading to the suggestion that TGF-(B might accelerate repair and restore function to these myocytes. Recent electron immunohistochemical and parallel cell fractionation studies have shown specific subcellular localization ofTGF-( I in mitochondria and contractile filaments of cardiac myocytes (9) . These findings suggest that TGF-(3 has an intrinsic, physiological role in myocytes, which is presently unknown.
Based on these observations, we postulated that TGF-,B might have an intrinsic role in regulating either cardiac myocyte contractility or energy metabolism (9) . Moreover, because ofour interest in defining the roles ofTGF-(3 in acute and chronic cardiac injury, we have examined whether exogenous TGF-# might have direct effects on myocyte function. Since mediators of acute and chronic cardiac damage, such as IL-1, have been shown to have suppressive effects on myocyte function (10), we also investigated whether TGF-,B might antagonize these effects of IL-1, analogous to its ability to oppose many of the actions of IL-on other cell types (11) (12) (13) (14) . We have used cultures of neonatal rat cardiac myocytes which beat spontaneously as a measure of myocyte function, and in this system, show that TGF-,3 plays an intrinsic role in stabilizing their beating rate in serum-free culture and that it is protective against the suppressive effects of IL-I on the contractility of myocytes.
Methods
Reagents. Porcine TGF-# I and 2 were obtained from R & D Systems, Inc. (Minneapolis, MN). Recombinant chicken TGF-#3 was expressed from a metallothionein promoter in NIH 3T3 cells and purified to homogeneity as described ( 15 ) . Unless Preparation ofneonatal cardiac myocytes. Myocytes were prepared from 2-d-old rat pups, using modifications of previously described methods ( 18) . Briefly, the dissected left ventricles of30-60 hearts were minced in PBS (without Ca"+ and Mg"+) containing 1% glucose, and digested for 0-min periods in a 50-ml spinner flask (Bellco Biotechnology, Vineland, NJ) in 10 ml of a solution consisting of 40 ml 0.25% trypsin (Gibco Laboratories, Grand Island, NY), 60 ml Hanks' salts without Ca"+ and Mg"+ (Gibco Laboratories) to which MgCI2 was added back to 0.81 mM, 3,500 U collagenase (type 2; Worthington Biochemical Corp., Freehold, NJ) and 10 mg deoxyribonuclease I (Worthington Biochemical Corp. Cross-linking ofTGF-jP to cell surfaceproteins. Either cardiac fibroblasts used at the first passage or freshly prepared purified myocytes were plated at a density of I X 106 cells per 35-mm dish coated with gelatin and cultured for 72 h in media containing 5% calfserum. At this point, cells were washed with binding buffer (DMEM, 25 mM Hepes, 1 mg/ml BSA, pH 7.4) and cross-linked to the iodinated TGF-,6 using disuccinimidyl suberate (Pierce Chemical Co., Rockford, IL) as previously described (22) .
Results
Initial studies using crude preparations ofmyocytes cultured in medium containing 5% serum on plates coated with gelatin demonstrated that IL-Ij# (0.3 to 5 ng/ml, added at t = 0), suppressed the beating rate ofthe cells measured 24 h later; this inhibition was overcome by the addition of TGF-,Bl (5 ng/ ml). TGF-# I was equally effective whether it was added 18 h before or simultaneously with the IL-lI3 (not shown).
Since these cultures contained variable numbers of cells other than myocytes, we purified the myocytes further on Percoll gradients (Sigma Chemical Co.) (19, 20) . Moreover, to characterize the nature of the response more precisely, myocytes were switched to a defined serum-free medium 72 h after the initial plating. At the time of changeover to serum-free conditions with appropriate growth factor additions (t = 0), the neonatal myocytes were subconfluent and were beating strongly and synchronously, usually at rates ranging from 120 to 150 bpm. In contrast to our earlier results, culture of these purified myocytes on wells coated with gelatin showed only minor effects of the added growth factors (Fig. 1, middle) ; however, when these same myocytes were cultured together with cardiac fibroblasts, in an attempt to mimic the initial experiments with the unfractionated myocytes, the suppressive effects of IL-13 and the protective effects of TGF-# I were once again observed (Fig. 1, left) . To ascertain whether both cultured neonatal cardiac myocytes and fibroblasts displayed cell surface receptors for TGF-fl, iodinated TGF-,3s were cross-linked to each ofthese cell populations, the cells were lysed, and the pattern ofbinding examined after electrophoresis on SDS gels. As shown in Fig. 2 , both myocytes and fibroblasts displayed the characteristic pattern of cross-linking of TGF-/3 to receptors, showing all three types of binding proteins (23, 24) . Although the relative proportions of the presumed signaling receptors (types I and II) to that of the cell-surface proteoglycan (type III) varied for the two cell types, each cell type appeared to bind all three TGF-3 isoforms similarly. These data suggest that cardiac myocytes and fibroblasts both express cellular receptors for TGF-fl.
We next showed that the effects of coculture of myocytes and fibroblasts could be reproduced by culture of the purified myocytes on matrix secreted by either cardiac fibroblasts (Fig.  1, right) or by NRK fibroblasts (data not shown), but not by simple addition of medium conditioned by cardiac fibroblasts exposed to the growth factor regimens (data not shown). Culture of the myocytes on purified laminin or fibronectin gave a pattern similar to that shown for myocytes cultured on gelatin (data not shown). These data demonstrate that the response of the cultured myocytes to cytokines can be modulated by the matrix on which they are grown, independent ofdirect cell-tocell contact between myocytes and fibroblasts. At the present time, it is not known whether these effects are mediated by cytokines or other bioactive factors sequestered in the fibroblast matrix, or whether they might result from subtle cytoskeletal and phenotypic changes in the myocytes after attachment to either gelatin or the native fibroblast matrix.
Both the actual beating rate and its rate ofdecline with time were dependent on the concentration of added TGF-,3 1 matrix. As shown in Fig. 3 , at any particular time, the beating rate was dependent on the concentration of added TGF-#31; concentrations of TGF-,B1 as low as 3 pM (78 pg/ml) still enhanced the beating rate of the myocytes relative to control.
In no case did the addition of TGF-#31 enhance the beating rate relative to the initial rate at the time of change of the cells to serum-free conditions. Rather, TGF-# 1 maintained the initial rate or lessened its decline during extended culture under serum-free conditions. Thus, myocytes cultured in the presence of TGF-3l at concentrations greater than 1 ng/ml were still beating at more than 50% their initial rate 40 h after the onset of serum-free conditions, in contrast to control cultures, in which beating had stopped entirely (Fig. 3) . After 72 h, 5 / 5 and 4/5 cultures of myocytes at TGF-/31 concentrations of 5 and 1.2 ng/ml, respectively, were still beating (data not shown). In contrast, myocytes cultured in the absence ofTGF-,B1 ceased to beat after approximately 24 h culture in serumfree medium (Fig. 3) . However, these myocytes maintained their capacity to beat, since beating was restored upon addition of serum (not shown). Each of the three TGF-/3 isoforms had equivalent stimulatory effects on the beating rate of the myocytes at 5 ng/ml (data not shown), although a complete doseresponse analysis for TGF-/3s 2 and 3 was not performed.
Significantly, careful observation of the cultures demonstrated not only that TGF-,Bl maintained the beating rate of myocytes cultured on fibroblast matrix, but also that myocytes cultured in the presence of TGF-# I generally had a more regular beating pattern than that of cells cultured in its absence. As shown in Table I , over 50% and 75% of the control or IL-,l/-treated myocyte cultures, respectively, were characterized by an irregular beating pattern, and an additional 1 1% and 25% of the same cultures, respectively, had either stopped beating or were beating at a rate greater than 200 bpm ("fibrillating"). In contrast, only 5% and 20% ofthe cultures treated with TGF-# I alone or TGF-#3I plus IL-13, respectively, had an irregular beating pattern, and no cultures in either of these groups had either stopped beating or were fibrillating.
To examine whether myocytes might be secreting factors capable of modulating their beating rate, cells were cultured under reduced volume conditions where any secreted factors would be more concentrated. Experiments in which equal numbers of myocytes were cultured identically on fibroblast matrix for the first 72 h and then shifted at t = 0 to either 1 ml or 0.25 ml of serum-free medium, showed that the beating rate ofcells cultured in the absence of added TGF-#l (control or IL-I treated) under either of these two conditions decreased similarly during the first 24 h of culture. However, during the next 24-h period, the beating rate of those myocytes treated with IL-and cultured in 0.25 ml, but not the standard l-ml vol of medium, increased significantly (P = 0.001, Fig. 4, A and B) .
In contrast the beating rates of myocytes cultured in the presence of added TGF-(tl were not appreciably affected by reduction of the volume of medium, over the same observation period. One possible explanation for these data is that stimulatory factors might be accumulating in the medium over time in culture.
Since TGF-# l appeared to replace the need for the putative endogenous factor, we examined whether TGF-fl might be secreted by the myocytes and whether an autocrine response to TGF-,B might play a role in maintaining the beating rate ofthe cells. As shown in Fig. 4 secreted by the myocyte cultures is TGF-#2 (data not shown).
The above experiments suggested that there might be a beating rate of the myocytes, which was met or exceeded only after extended culture in the more concentrated condition of the low volume cultures. A corollary would be that removal of TGF-# from the medium should suppress the intrinsic beating rate and accelerate the rate of decline of the beating rate. Indeed, as shown in Fig. 5 , addition of a monoclonal antibody that blocks the activity of TGF-#s 1, 2, and 3 markedly acceler- To investigate whether TGF-f3 was unique in promoting these observed effects, three other growth factors, namely PDGF BB, bFGF, and EGF, were assayed in a similar experimental design to determine their efficacy both in maintaining the basal beating rate of the myocytes in serum-free medium and in antagonizing the effects of IL-1,B (see Table II ). At early times, the results were somewhat variable from experiment to experiment, with PDGF BB and bFGF having a moderate positive effect on the beating rate. However, without exception, only those cultures treated with TGF-(3 were able to sustain a regular beating pattern after 19 to 48 h of culture. Relative effects of each of these growth factors were similar in the presence or absence of added IL-1. Thus, within this set of factors, TGF-(3 is unique in its ability to sustain rhythmic beating ofthe cultured myocytes for an extended period oftime in serum-free culture.
Discussion
In these experiments, we have demonstrated for the first time that exogenous TGF-,B is uniquely able to regulate the beating rate of cultured neonatal rat myocytes, both maintaining the regular rhythm and the rate of beating of cells cultured in serum-free medium. More importantly, we have demonstrated that cultured myocytes secrete relatively high levels of and that this endogenous TGF-j3 acts in an autocrine fashion to sustain the beating rate ofmyocytes cultured in serum-free medium. The data are consistent with our previous proposals that TGF-(3 might accelerate repair and restore function to myocytes which stain intensely for TGF-# 1 and are located at the margin of an infarcted area of the heart (2).
Our results also confirm that IL-1 suppresses myocyte contractility ( 10) (27) , or upregulation by TGF-, ofexpression ofthe IL-1 receptor antagonist as demonstrated in peripheral blood monocytes (28) . At a different level, TGF-(3 has been shown to increase matrix protein synthesis and to decrease protease secretion (29) , while the corresponding effects of IL-1 are exactly opposite (30) . The rather prolonged time frame of our observed effects of these cytokines on myocyte function is consistent with any of these mechanisms.
TGF-ft administered systemically after experimental infarction has been shown to have cardioprotective effects (31, 32) . Similar protective effects of TGF-# have been demonstrated in a model of splanchnic ischemia-reperfusion injury (32) . One ofthe effects ofsystemic TGF-# administration is to suppress release of IL-I and TNFa into the circulation after reperfusion. However, these effects have been suggested to be mediated indirectly via the ability of TGF-# to preserve and stabilize endothelial function and to inhibit endothelial adhesiveness for neutrophils (32, 33) . This mechanism therefore is distinct from the direct antagonism by TGF-# of the effects of IL-1(3 on cardiac myocytes that we have described here.
Our data leave open the question of the mechanism of action of TGF-# on the myocytes, since preliminary attempts to identify such mechanisms have been unsuccessful. Thus, measurement of cellular ATP levels showed no significant differences whether myocytes were treated with TGF-fl or with IL-13 (data not shown). Moreover, changes in cAMP levels in response to treatment with isoproterenol (10) were suppressed equivalently relative to control in myocytes treated with either TGF-(3 or IL-1( (data not shown), suggesting that changes in cAMP could not directly be related to the observed opposite effects of TGF-(3 and IL-I on the beating rate of the myocytes.
Likewise, since both TGF-fl and bFGF have similar effects on expression of a and ,B-myosin heavy chain genes by these cells ( 1, 18) , but different effects on their beating rates (Table II) , effects ofthese two cytokines on differentiation cannot explain the observations reported here. Lastly, investigations into possible effects ofTGF-(3 on regulation ofcalcium in myocytes demonstrated that whereas culture ofmyocytes in low calcium concentrations (0.2 to 1 mM) suppressed the beating rate of the cultures in a concentration-dependent manner, the suppression could not be overcome by TGF-# added either 18 h previous to or at the same time as the downshift of the calcium (data not shown).
The ability ofmatrix to regulate the actions ofcytokines on cell phenotype and cell function has been observed in numerous in vitro systems (34) . For example, type IV collagen, fibronectin, and laminin coatings differentially affect the growth of cultured endothelial cells, and the inhibition of the growth of these cells by TGF-,3 is thought to be mediated, in part, by its ability to enhance cellular fibronectin secretion (35) . Moreover, both TGF-#lI and IL-IB have been shown to regulate expression of cell adhesion integrin receptors on a variety of cell types (36) (37) (38) . If these cytokines were able to modulate differentially integrin receptor expression on neonatal myocytes, it could subtly affect the shape or spreading, and consequently the contractility, ofmyocytes cultured on the complex, native fibroblast matrix compared to gelatin (principally denatured type I collagen), laminin, or fibronectin. In addition, cytokines such as TGF-,3 (39, 40) and FGF (41, 42) can bind to proteoglycan matrix components. Whether the altered contractile response patterns to exogenous cytokines of myocytes cultured on a more homogeneous, defined matrix compared to a native fibroblast matrix (Fig. 1 ) might result from effects of these or other unknown sequestered cytokines cannot be determined at the present time. Although it has not escaped our attention that disorders of the collagen matrix result in compromised mechanical properties ofthe heart (43-45), the relationship of our in vitro model system to that of a complex organ in vivo is unclear.
Future directions ofthis research will be focused on characterizing specific roles ofthe three TGF-3 isoforms in both basal function of cardiac myocytes and their response to injury and stress. Moreover, we hope to identify the mechanisms ofaction of TGF-#t and IL-1 on myocytes, including the modulating role of the matrix, with the ultimate goal of increasing our understanding of the role of these cytokines in the clinical setting of the response of the heart to both acute and chronic injury.
